Germline HRR Gene Panel

Germline mutations in HRR pathway genes can increase an individual’s susceptibility to hereditary cancers. The Germline HRR Gene Panel is a comprehensive genetic test, analyzed using Next-Generation Sequencing (NGS), that evaluates key HRR genes to detect variations or pathogenic changes that may predispose individuals to cancer.

This test provides insights into inherited risks for cancers such as breast, ovarian, pancreatic, and prostate cancer. It supports genetic counseling, risk assessment, and personalized treatment decisions, including targeted therapies or preventive interventions. By identifying germline mutations, the panel aids doctors in developing tailored management strategies and guiding family planning decisions for at-risk individuals.

Doctors may recommend the Germline HRR Panel for individuals with a personal or family history of hereditary cancers, early-onset cancers, bilateral cancers, or known genetic risk factors. The test is also useful for patients who wish to understand their inherited risk and plan preventive strategies.

For this test, it is important to submit the clinical history, histopathology report, previous test results, and a doctor’s prescription at the time of sample collection. The Tata 1mg consolidated Test Requisition Form (TRF) must also be duly filled and submitted.

Lab test results may vary across different laboratories. Abnormal test results require an expert interpretation. Therefore, never try to self-medicate at home based solely on these results, and always consult a doctor for proper understanding of the test results.

Note: Genetic counseling can be provided. If interested, please send the request to this email id:[email protected]